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HIV infects macrophages and microglia in the central nervous system (CNS), which express lower levels of CD4 than CD4+ T cells in
peripheral blood. To investigate mechanisms of HIV neurotropism, full-length env genes were cloned from autopsy brain and lymphoid tissues
from 4 AIDS patients with HIV-associated dementia (HAD). Characterization of 55 functional Env clones demonstrated that Envs with reduced
dependence on CD4 for fusion and viral entry are more frequent in brain compared to lymphoid tissue. Envs that mediated efficient entry into
macrophages were frequent in brain but were also present in lymphoid tissue. For most Envs, entry into macrophages correlated with overall
fusion activity at all levels of CD4 and CCR5. gp160 nucleotide sequences were compartmentalized in brain versus lymphoid tissue within each
patient. Proline at position 308 in the V3 loop of gp120 was associated with brain compartmentalization in 3 patients, but mutagenesis studies
suggested that P308 alone does not contribute to reduced CD4 dependence or macrophage-tropism. These results suggest that HIV adaptation to
replicate in the CNS selects for Envs with reduced CD4 dependence and increased fusion activity. Macrophage-tropic Envs are frequent in brain
but are also present in lymphoid tissues of AIDS patients with HAD, and entry into macrophages in the CNS and other tissues is dependent on the
ability to use low receptor levels and overall efficiency of fusion.
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Human immunodeficiency virus type 1 (HIV) infects the
central nervous system (CNS) in the early stages of disease (An
et al., 1999; Davis et al., 1992) and causes HIV-associated
dementia (HAD) or milder forms of neurocognitive impairment
in 10–20% of AIDS patients (Gonzalez-Scarano and Martin-
Garcia, 2005; Kaul et al., 2001, 2005; McArthur et al., 2003;
Sacktor et al., 2002). Highly active anti-retroviral therapy
(HAART) has reduced the incidence of HAD (d'Arminio⁎ Corresponding author. Dana-Farber Cancer Institute, JFB 816, 44 Binney
St., Boston, MA 02115, USA. Fax: +1 617 632 3113.
E-mail address: dana_gabuzda@dfci.harvard.edu (D. Gabuzda).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.09.036Monforte et al., 2004; Dore et al., 1999; Sacktor et al., 2001,
2002), but the prevalence of minor cognitive and motor
disorders (MCMD) has been increasing as HIV-infected
individuals survive for a longer time on anti-retroviral therapies
(Dore et al., 2003; McArthur et al., 2003; Neuenburg et al.,
2002; Valcour et al., 2004). Most current antiviral drugs have
relatively poor CNS penetration. Thus, the CNS is an important
reservoir for long-term viral persistence and neurocognitive
impairment continues to be a significant complication of HIV
disease.
HIV enters the CNS via trafficking of infected monocytes
and lymphocytes across the blood-brain barrier (reviewed in
Dunfee et al., 2006; Gonzalez-Scarano and Martin-Garcia,
2005). The main target cells for HIV infection in the CNS are
106 E.R. Thomas et al. / Virology 360 (2007) 105–119macrophages and microglia. HIV entry is initiated by the viral
envelope glycoprotein gp120 binding to CD4. Structural
rearrangements induced by CD4 binding allow subsequent
interaction with a chemokine coreceptor, usually CCR5 or
CXCR4, leading to further conformational changes and fusion
of viral and target cell membranes (Deng et al., 1996; Dragic et
al., 1996; Oberlin et al., 1996; Trkola et al., 1996; Wu et al.,
1996). Coreceptor usage is a major determinant of cellular
tropism. CCR5 using (R5) viruses infect CD4+ T cells and
macrophages, and CXCR4 using (X4) viruses infect CD4+ T
cells and T cell lines. However, CCR5 usage alone does not
predict macrophage tropism (M-tropism) (Cheng-Mayer et al.,
1997; Cunningham et al., 2000; Dittmar et al., 1997; Gorry et
al., 2001; Hung et al., 1999). A subset of R5 viruses do not
productively infect macrophages (Gorry et al., 2001; Li et al.,
1999). Furthermore, some M-tropic HIV strains use CXCR4 for
entry in macrophages and microglia (Ancuta et al., 2001; Gorry
et al., 2001; Koning et al., 2001; Naif et al., 2002; Simmons et
al., 1998; Singh et al., 2001; Yi et al., 1998, 1999). Receptor
density also determines the susceptibility of primary cells and
cell lines to HIV infection (Fear et al., 1998; Kuhmann et al.,
2000; Platt et al., 1998; Rana et al., 1997; Reynes et al., 2001;
Tuttle et al., 1998). Thus, while CCR5 is the main coreceptor for
HIV entry in macrophages, viral determinants independent of
those that influence coreceptor usage also influence macro-
phage tropism.
Macrophages and microglia express lower levels of CD4
than CD4+ T cells in peripheral blood (Di Marzio et al., 1998;
Dick et al., 1997; Graziani-Bowering and Filion, 2000; Jordan
et al., 1991; Kazazi et al., 1989; Lewin et al., 1996; Martin-
Garcia et al., 2002; Peudenier et al., 1991a, 1991b; Tuttle et al.,
1998; Wang et al., 2002; Williams et al., 1992). Previous studies
identified a few brain-derived HIV viruses from HAD patients
that replicate efficiently in macrophages and microglia and have
reduced dependence on CD4 and/or CCR5 levels for entry
(Gorry et al., 2001, 2002; Martin-Garcia et al., 2006; Peters et
al., 2004). Reduced CD4 or CCR5 dependence may therefore
contribute to HIV neurotropism and neurovirulence. However,
whether HIV Envs that have reduced dependence on CD4 and
CCR5 levels are more frequent in brain compared to other
tissues remains unclear.
Genetic evolution of HIV within the brain is distinct from
that in lymphoid tissues and other organs (Chang et al., 1998;
Donaldson et al., 1994; Gartner et al., 1997; Gorry et al., 2001;
Hughes et al., 1997; Korber et al., 1994; Shapshak et al., 1999;
van't Wout et al., 1998; Wong et al., 1997). Genetic
compartmentalization of viral variants in the brain suggests
that adaptive evolution may occur in the CNS in response to
unique constraints of the brain microenvironment, such as
different target cell populations and immune selection pres-
sures. Strain et al. (2005) reported several residues in the C2-V3
region of Env associated with compartmentalization in the
cerebrospinal fluid (CSF). However, other studies failed to
identify sequence differences associated with brain compart-
mentalization (Ohagen et al., 2003; Reddy et al., 1996), and Env
sequences that enhance HIV neurotropism have not been
identified.To investigate genetic and functional characteristics of Envs
in brain versus lymphoid tissues, full-length env genes were
amplified from autopsy brain and lymphoid tissues from 4
AIDS patients with HAD. Envs with reduced dependence on
CD4 levels were more frequent in brain but were also present in
lymphoid tissue. The capacity of Envs from both brain and
lymphoid tissues to mediate entry into macrophages correlated
with overall fusion activity at all levels of CD4 and CCR5.
Proline at position 308 in the V3 region of gp120 was associated
with brain compartmentalization in 3 patients, but mutagenesis
studies suggested that P308 alone did not contribute to the
reduced CD4 dependence or macrophage-tropism of brain-
derived Envs. Thus, HIV adaptation to replicate in the CNS
microenvironment selects for Envs with reduced CD4 depen-
dence and increased fusion activity. Macrophage-tropic Envs
are frequent in brain but are also present in lymphoid tissues of
HAD patients, and entry into macrophages is influenced by the
capacity to use low receptor levels and overall efficiency of
fusion.
Results
HIV envelopes with reduced dependence on CD4 levels are
more frequent in brain compared to lymphoid tissues
To determine whether HIV Envs with reduced dependence
on CD4 or CCR5 levels are more frequent in brain compared
to lymphoid tissues, full-length HIV env genes were cloned
directly from autopsy brain (frontal lobe or basal ganglia) and
lymphoid (lymph node or spleen) tissues from 4 AIDS
patients with HAD (MACS2, MACS3, UK1 and UK7) (Table
1). Eight to 40 Env clones from each tissue sample were
screened for functional activity in single-round infection
assays by pseudotyping onto NL43Δenv-GFP and detecting
infection of CCR5/CXCR4-positive Hela/CD4 cells (clone
JC53). By this approach, 10 tissue samples from 4 AIDS
patients yielded 55 functional Env clones (n=35 brain and 20
lymphoid). All 55 Env clones used CCR5 to enter cells, 2
weakly used CCR3 and none used CXCR4 (Table 1). None of
the Env clones mediated CD4-independent infection in Cf2
cells expressing CCR5. This pattern of coreceptor usage is
consistent with the R5 phenotype of primary viruses
previously isolated from these tissue samples (Gorry et al.,
2001; and P. Gorry and D. Gabuzda, unpublished data).
To investigate the frequency of Envs in brain versus
lymphoid tissue that can use low levels of CD4 or CCR5 to
mediate fusion, we performed cell-to-cell fusion assays with
Cf2 cells expressing low (mean fluorescent intensities (MFI) 18
(range 17–21) and 52 (range 35–86); 30% and 47% positive for
CD4 and CCR5, respectively, as determined by flow cytome-
try), medium (MFI 124 (116–132) and 178 (149–193); 55%
and 69%) or high (MFI 773 (689–883) and 516 (459–584);
76% and 78%) CD4 and CCR5. Envs from brain and lymphoid
tissue from the same patient were assayed simultaneously on the
same populations of transfected Cf2 cells. The well-character-
ized ADA and YU2 Envs cloned from macrophage-tropic blood
viral isolates were used as controls in parallel experiments. For
Table 1
Characteristics of patients and envelope clones
Patient Risk factor a CD4 count b Antiretroviral therapy HIV encephalitis Giant cells Autopsy tissue c Viral load d No. of clones Coreceptor usage e
MACS2 MH 52 AZT Moderate + FL 1200 8 R5 (R3)
LN 8700 3 R5
SP 2400 3 R5
MACS3 MH 95 None Moderate + FL 660 8 R5
LN 100800 6 R5
UK1 IVDU 87 ddc (1mo) Moderate + FL 51500 7 R5
BG 44800 4 R5
SP 1400 6 R5
UK7 IVDU 90 AZT Severe + FL 27800 8 R5
LN 300 2 R5
a MH, male homosexual; IVDU, intravenous drug user.
b Cells per microliter.
c FL, frontal lobe; BG, basal ganglia; LN, lymph node; SP, spleen.
d HIV Gag DNA copies per 106 cells. Viral load for MACS2FL, UK1FL and UK1BG is an average of the viral load for 2 samples.
e Coreceptor usage was determined by infection of Cf2 cells expressing CD4 and either CCR5, CXCR4 or CCR3. Parenthesis indicates weak coreceptor usage.
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with greater levels of overall fusion for brain compared with
lymphoid Envs at all levels of CD4 and CCR5 (Fig. 1A). To
determine whether there are differences between brain and
lymphoid Envs in their relative use of low CD4 levels, we
calculated the ratio for Env-mediated fusion with cells
expressing low versus high CD4 (Fig. 1B). MACS2 brain
Envs (n=8) fused more efficiently with cells expressing low or
medium CD4 levels than did MACS2 lymphoid Envs (n=6)
(Fig. 1A). Seven of 8 MACS3 brain Envs and 7 of 8 UK7 brain
Envs mediated fusion at low CD4 levels compared with only 1
of 6 MACS3 lymphoid Envs (LN2) and none of the UK7
lymphoid Envs (Fig. 1). In contrast, the ability of UK1 brain
versus lymphoid Envs to use low CD4 levels did not segregate
according to tissue of origin. Both brain (8/11) and lymphoid
(3/6) (SP2, SP6-20, SP6-22) UK1 Envs mediated fusion at low
CD4. In total, 30 of 35 brain Envs but only 4 of 20 lymphoid
Envs (p<0.01, Fisher's exact test) mediated fusion with cells
expressing low CD4 levels.
In addition to mediating fusion at low CD4 levels, 11 UK1
Envs had an enhanced capacity to induce fusion with cells
expressing low CCR5 levels compared to MACS2, MACS3 and
UK7 Envs (Fig. 1A). Furthermore, MACS2 and UK7 brain
Envs were more efficient than lymphoid Envs at mediating
fusion at low CCR5 levels when CD4 was at low or medium
levels. In contrast, MACS3 brain Envs were only marginally
more efficient than lymphoid Envs at mediating fusion at low
CCR5 levels, and only when CD4 levels were also low (Fig.
1A). Therefore, 3 patterns emerged from analyses of Envs from
these patients: (1) In MACS2 and UK7, brain Envs were more
efficient than lymphoid Envs at mediating fusion at low CD4
and CCR5 levels; (2) in MACS3, brain Envs were more
efficient than lymphoid Envs at mediating fusion at low CD4
but not CCR5 levels; and (3) in UK1, Env clones from both
brain and lymphoid tissue had a markedly enhanced capacity to
mediate fusion at low levels of CD4 and CCR5.
To test the dependence of brain and lymphoid Envs on CD4
and CCR5 levels when mediating virus infection, we performed
single round virus entry assays with Cf2 cells expressing low,medium or high CD4 and CCR5. For these assays, we tested 33
genetically distinct Envs exhibiting a range of abilities to use
different CD4 levels similar to that of all Envs cloned from the
same tissue sample. Envs that used low CD4 levels in cell-to-
cell fusion assays (Fig. 1) also mediated detectable infection of
cells expressing low CD4 levels in infection assays (Fig. 2).
MACS2, MACS3 and UK7 brain Envs had a greater capacity to
infect cells expressing low CD4 than did lymphoid Envs. In
contrast, infection mediated by UK1 Envs showed no clear
distinction between brain versus lymphoid Envs in the ability to
use low CD4, similar to results observed in fusion assays. All
UK1 brain and lymphoid Envs, except spleen clone 20, infected
cells expressing low CD4 more efficiently than the majority of
MACS3, UK1 and UK7 brain or lymphoid Envs (Fig. 2). Brain
Envs had higher infectivity ratios for cells expressing low
versus high CD4 compared to lymphoid Envs (2p<0.001,
Wilcoxon rank-sum test, with combined data stratified by
patient). When data from individual patients were analyzed,
only MACS3 showed a statistically significant difference
between brain and lymphoid Envs (2p=0.016). In contrast, no
segregation between brain and lymphoid Envs was observed for
infection of cells expressing low versus high levels of CCR5
(data not shown). However, similar to data obtained in cell–cell
fusion assays, UK1 Envs from both brain and lymphoid tissue
efficiently used low levels of CCR5 to mediate infection, and
brain Envs from MACS2 and UK7 used low CCR5 more
efficiently than lymphoid Envs (data not shown). Western blot
analysis of Env expression demonstrated some variability in
levels of gp160 expression and processing (Fig. 3 and data not
shown). However, these differences did not correlate with
differences in the ability to mediate fusion at low CD4 or CCR5
levels. These results demonstrate that Envs that can use low
levels of CD4 and CCR5 for fusion and infection are more
frequent in brain compared to lymphoid tissue from the same
patient.
To assess the ability of brain and lymphoid Envs to mediate
entry into macrophages, we performed single round entry
assays. Equivalent amounts of luciferase reporter viruses
pseudotyped with brain or lymphoid Envs were used to infect
Fig. 1. Cell–cell fusion mediated by brain and lymphoid Envs. (A) 293Tcells expressing brain (red) or lymphoid (blue) Envs fromMACS2, MACS3, UK1 and UK7 or
the ADA or YU2 Envs were mixed with Cf2luc cells expressing low, medium (Med) or high (Hi) levels of CD4 and CCR5 as indicated. Fusion was measured as
luciferase counts in lysed cells following 12 h incubation. Control fusion of 293T cells with pCR3.1 in place of Env, indicating background levels, is represented by
grey diamonds. Luciferase activity less than 1.5-fold above the background level obtained with the no Env-negative control (pCR3.1) was considered negative. Data
are expressed as means of duplicate wells from a single experiment and are representative of results from 2 to 3 independent experiments. Error bars represent standard
deviations. (B) Fusion activity of brain (open symbols) and lymphoid (closed symbols) Envs from MACS2, MACS3, UK1 and UK7 expressed as a ratio of Env-
mediated fusion with cells expressing low compared to high levels of CD4 and medium levels of CCR5.
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broad range of entry levels into MDM. Levels of Env-mediated
entry into MDM did not clearly segregate according to tissue of
origin or reduced CD4 dependence. (Fig. 4A). UK1 Envs with a
greatly enhanced capacity to use low CD4 and CCR5 levels,
SP6-20 and BG3-13, also mediated high levels of entry into
MDM, suggesting that their reduced dependence on CD4 and
CCR5 levels contributed to their increased M-tropism. Levels of
entry into MDM mediated by individual Env clones across the
entire data set correlated with their levels of overall fusion
activity at low, medium, and high levels of CD4 (Fig. 4B).Together, these results suggest that efficient entry into MDM is
dependent on several factors that include the ability of Envs to
use low receptor levels and additional factors that influence the
overall efficiency and kinetics of fusion.
Analysis of HIV Env sequences
To investigate genetic relationships between env genes in
brain and lymphoid tissue, we performed phylogenetic analysis
of full-length gp160 nucleotide sequences. No stop codons or
frame shifts were observed in the env open reading frames. Env
Fig. 2. Virus entry mediated by brain and lymphoid Envs. Luciferase reporter
viruses were pseudotyped with brain (open symbols) or lymphoid (closed
symbols) Envs from MACS2, MACS3, UK1 and UK7. Entry into Cf2 cells is
expressed as a ratio of virus entry on cells expressing low compared to high
levels of CD4 and high levels of CCR5. Actual values for luciferase counts in
cells expressing low or high CD4 ranged from 823-101393, 788-34703, 1053-
1072087 and 315-58126 for Envs from MACS2, MACS3, UK1 and UK7,
respectively. Background levels were determined as in Fig. 1.
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previously obtained by PBMC coculture (Dunfee et al., 2006;
Gorry et al., 2002) were included for comparison. gp160
sequences grouped by patient were most closely related to other
sequences from the same patient, with no evidence for possible
contaminants (Fig. 5). Distinct env populations according to
tissue of origin confirmed genetic partitioning of Env sequences
between brain and lymphoid tissue (Fig. 5). Unexpectedly, Env
clones from the MACS2 primary brain isolate, which do not
have reduced CD4 dependence, clustered with lymphoid ratherFig. 3. gp160 and gp120 expression by brain and lymphoid Env clones. Env expressio
anti-gp120 rabbit sera. Positions of gp160 and gp120 bands are indicated on the rigthan brain Envs. In contrast, Env clones from the UK1 and UK7
primary brain isolates, which have reduced CD4 dependence,
clustered with Env clones amplified directly from brain tissue.
Deletions and insertions in gp41 from the UK1 and MACS2
brain isolate-derived Envs (Gorry et al., 2002) were rare in
functional envs amplified directly from tissues, with a trun-
cation near the gp41 C-terminus observed only in UK7
lymphoid clone 7-6. The number of predicted N-linked
glycosylation sites in brain and lymphoid Envs ranged from
23 to 28 in gp120, and 4 to 5 in gp41 (Table 2). There was no
consistent difference in the number or distribution of predicted
N-linked glycans between brain and lymphoid Envs. Screening
for hypermutation in brain and lymphoid env genes was
performed using HYPERMUT to compare the rate of G to A
transitions in each env sequence compared to the tissue
consensus (Rose and Korber, 2000). Overall, the hypermutation
rate was low (<5%) with no significant difference between
brain and lymphoid env genes. However, we excluded non-
functional Env clones from the data set, which would likely
exclude highly mutated Env sequences. The highest frequency
of G to A transitions compared to the tissue consensus was seen
in 3 UK1 envs, BG3-10, SP5-5 and SP5-11. Overall, these envs
were the most genetically distinct compared to other Envs from
this patient (Fig. 5). These analyses confirm genetic compart-
mentalization of full-length, functional Env sequences and
underscore the importance of viral genotype and phenotype
analysis without prior in vitro amplification.
Proline at position 308 in the V3 loop of HIV gp120 is
associated with brain Env
To identify specific amino acid residues that are more
frequent in brain compared to lymphoid Envs, we performed a
signature pattern analysis of all gp160 amino acid sequences in
the data set using VESPA (Korber and Myers, 1992). Proline atn and processing of gp160 to gp120 in 293T cells detected by Western blot with
ht.
Fig. 4. Virus entry into macrophages mediated by brain and lymphoid Envs. (A) Luciferase reporter viruses were pseudotyped with brain (open bars) or lymphoid (grey
bars) Envs from MACS2, MACS3, UK1 and UK7. Entry into macrophages was measured as luciferase counts in lysed cells following incubation for 6 days. Data are
expressed as means from duplicate wells and are representative of results in 2 different donors. Error bars represent standard deviations. (B) Brain (open symbols) and
lymphoid (grey symbols) entry intoMDM (y axis) correlates with levels of fusion between Env-expressing 293Tcells and Cf2luc cells expressing low, medium or high
levels of CD4 and high CCR5 (x axis). Pearson's correlation coefficient (r2) and p values are shown.
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the crown of the V3 loop, was associated with compartmenta-
lization in brain across the entire data set (p<0.01, Fisher's
exact test). Proline at position 308 was present in 100% (27/27)
of brain Envs, but only 28% (4/14) of lymphoid Envs in 3
patients (MACS2, UK1 and UK7) (Fig. 6). All lymphoid Envs
with proline at position 308 were from UK1 (SP2, 20, 6-20 and
6-22). All MACS3 Env clones contained histidine at position
308. The clade B consensus at position 308 is histidine, which is
found in 53% of clade B V3 sequences, while proline is found at
position 308 in only 14% of clade B V3 sequences (n=23,516;
http://hiv.lanl.gov). In 8 published studies of matched brain and
lymphoid or blood samples, proline at position 308 is present in
a higher proportion of brain (69/135, 51.1%) compared with
lymphoid Envs (45/125, 36.8%) (n=13 subjects that had P308
in any Env, p=0.01, Fisher's exact test) (Donaldson et al.,
1994; Gartner et al., 1997; Korber et al., 1994; Martin-Garcia et
al., 2006; Morris et al., 1999; Peters et al., 2004; van't Wout et
al., 1998; Wang et al., 2001). Therefore, proline at position 308
in the V3 region of gp120 is more frequent in brain than in
lymphoid tissue.Reduced CD4 and CCR5 dependence of brain Envs is not
altered by mutation of P308
To assess the influence of P308 on functional character-
istics of brain-derived Envs, mutagenesis was used to
change the proline to histidine at this position in the
MACS2 (FL8-12) and UK7 (Br34) brain Env clones. We
investigated whether introducing this mutation altered the
capacity of these Envs to mediate fusion or infection with
cells expressing low CD4 or CCR5 levels. The mutant Envs
containing H308 were expressed and processed at levels
similar to those of the parental Envs (Fig. 7B). There was
no significant difference in the efficiency of fusion or
infection of Cf2 cells expressing low, medium or high CD4
or CCR5 when P308 was changed to histidine (Fig. 7A).
Additionally, we found no consistent enhancement or
reduction of entry into MDM during single round infection
assays using MDM from different donors when the H308
mutation was introduced (Fig. 7C). Thus, P308 does not
contribute to the reduced CD4 dependence of these 2 brain-
derived Envs.
Fig. 5. Phylogenetic analysis of full-length HIV env nucleotide sequences from autopsy tissue samples and viral isolates. Env sequences amplified directly from brain
and lymphoid tissues are color-coded grey and black, respectively. Env sequences for MACS2, UK1 and UK7 brain viral isolates obtained by PBMC co-culture are
shown in black with the prefix Br. Numbers associated with each branch are bootstrap values, which represent the number of trees, out of 1000 replicates performed, in
which the same branching order was found. Only values above 900 for the major branches are shown. Branch lengths are proportional to the amount of sequence
divergence. Scale bars indicate 1% sequence divergence. FL, frontal lobe; BG, basal ganglia; LN, lymph node; SP, spleen.
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brain Envs to entry inhibitors
Mutation of histidine to proline at position 308 in gp120 of a
primary HIV isolate was reported in a viral escape mutant that
developed resistance to the small molecule CCR5 inhibitor
AD101 after in vitro passage in the presence of this drug
(Kuhmann et al., 2004; Trkola et al., 2002). The resultant virus
was still dependent on CCR5 but contained amino acid
substitutions that altered the manner in which Env interacts
with CCR5 (Marozsan et al., 2005; Trkola et al., 2002). A
change from histidine to proline at position 308 conferred an
∼500-fold increase in drug resistance (Kuhmann et al., 2004).Table 2
Predicted N-linked glycosylation sites in Env clones from brain and lymphoid
tissue
V1 V2 V3 V4 gp120 gp41
MACS2 Brain 1 1 1 5 23 5
Lymphoid 1 2 1 5 25 5
MACS3 Brain 2 2 1 5 26 5
Lymphoid 2 2 1 4 25 4
UK1 Brain 4 2 1 6 27 5
Lymphoid 4 2 1 6 27 5
UK7 Brain 2 2 1 4 25 4
Lymphoid 1 2 1 4 23 4
Shown is the median number of predicted N-linked glycosylation sites in all
Envs from the indicated tissue.Therefore, we tested the sensitivity of viruses pseudotyped with
Envs containing P308 versus H308 to the CCR5 inhibitors
AD101, TAK-779 and the anti-CCR5 MAb 2D7 and the HIV
fusion inhibitor T20. MACS2 and UK7 brain Envs showed no
difference in sensitivity to these inhibitors when P308 was
changed to histidine (Table 3). Therefore, in the context of 2
brain-derived Envs, P308 did not affect sensitivity to CCR5
inhibitors. Thus, the contribution of proline at position 308 to
development of resistance to coreceptor inhibitors is context
dependent, and additional determinants may be necessary to
generate resistance in genetically different Envs from patients.
The brain is an immunologically privileged site with reduced
selection pressure from cellular and humoral immunity to
constrain viral evolution. Viral adaptation to the brain
microenvironment can result in enhanced sensitivity to
neutralizing antibodies (Martin et al., 2001; Song et al.,
2004). Therefore, we tested whether introducing the H308
mutation into the UK7 and MACS2 brain Envs alters sensitivity
to neutralization by monoclonal antibodies directed against the
CD4 binding site (b12), coreceptor binding site (17b and 19e) or
gp41 (2F5), and by sera from 4 HIV-infected individuals. The
UK7 brain Env was more sensitive to b12 neutralization, but
more resistant to neutralization by patient sera, compared with
the MACS2 Env (Table 3). The 17b and 19e MAbs targeting the
coreceptor binding site did not reach the IC50 for these Envs at
the highest concentration tested (10 μg/ml) in the presence or
absence of sCD4 (data not shown). We found no difference in
Fig. 6. Amino acid alignment of HIV Env V3 loop regions of brain and lymphoid Env clones with the clade B consensus. Tissue of origin and number of clones with
each sequence are indicated to the left and right of each sequence, respectively. Numbering is relative to the Hxbc2 Env sequence. Dots indicate residues identical to the
clade B consensus, and dashes indicate gaps. Proline at position 308 is shaded in grey. LN, lymph node; SP, spleen.
Fig. 7. Fusion and entry of brain Envs with a proline to histidine substitution at position 308. (A) 293T cells or luciferase reporter viruses pseudotyped with wild-type
and mutant brain Envs from MACS2 (8-12) and UK7 (Br34) were mixed with Cf2luc or Cf2 cells, respectively, expressing low, medium or high levels of CD4 and
CCR5 as indicated. Fusion and infection were measured as luciferase counts in lysed cells following 12 or 72 h incubation, respectively. Background levels were
determined as in Fig. 1. (B) Wild-type and mutant Env expression and processing of gp160 to gp120 in 293Tcells detected byWestern blot with anti-gp120 rabbit sera.
Positions of gp160 and gp120 bands are indicated on the right. (C) Luciferase reporter viruses pseudotyped with wild-type and mutant brain Envs fromMACS2 (8-12)
and UK7 (Br34) were used to infect MDM from 2 representative donors. Entry was measured as luciferase counts in lysed cells following 6 days incubation. Data are
expressed as means from duplicate wells. Error bars represent standard deviations.
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Table 3
Neutralization of pseudotyped luciferase viruses by entry inhibitors, MAbs and HIV-infected patient sera
AD101a TAK779a 2D7b T20b b12b 2F5b PS1c PS2c PS3c PS4c
MACS2 8-12 24.7 354 0.56 0.32 5.22 12.2 >50 393 128 131
8-12/308H 29.8 380 0.53 0.35 4.53 10.3 >50 219 147 200
UK7 Br34 110.3 357 3.44 0.43 0.14 10.3 >50 101 >50 >50
Br34/308H 179.7 324 4.20 0.61 0.14 10.8 >50 143 >50 >50
IC50 titers at which luciferase production was reduced by 50%.
a nM, bμg/ml, creciprocal serum dilution.
113E.R. Thomas et al. / Virology 360 (2007) 105–119the sensitivity to b12, 17b, 19e or 2F5 neutralization in these
Envs when P308 was changed to histidine. Additionally, there
was no difference in neutralization sensitivity to sera from 3
HIV positive patients (Table 3). However, MACS2 brain Env
containing H308 was more resistant to neutralization by sera
from an HIV-infected patient (PS2) compared to the parental
Env containing P308, with a 2-fold increase in the IC50 (Table
3). Previous studies have demonstrated a proline substitution at
position 308 associated with enhanced neutralization sensitivity
(Quinnan et al., 1999; Young et al., 2004; Zhang et al., 2002)
suggesting that alteration of this residue in some Envs may
increase exposure of neutralization sensitive epitopes. Thus,
persistence and compartmentalization of this mutation in the
brain may be a consequence of lower neutralizing antibody
levels in the CNS compared to the periphery.
Discussion
In this study, we characterized HIV Env clones from brain
and lymphoid tissue of 4 AIDS patients with HAD and
demonstrated that Envs with reduced dependence on CD4
levels are more frequent in brain compared with lymphoid tissue
from the same patient. Thirty of 35 brain Env clones had
reduced dependence on CD4 in cell–cell fusion and single
round infection assays, while only 4 of 20 lymphoid Envs had
reduced CD4 dependence. Previous studies identified HIV Envs
with reduced dependence on CD4 levels only in brain (Gorry et
al., 2001, 2002; Martin-Garcia et al., 2006; Peters et al., 2004).
Here we report that 4 lymphoid Envs from 2 HAD patients
(3 UK1 spleen Envs and 1 MACS3 lymph node Env) have a
similar phenotype. Furthermore, 5 brain Envs from UK1, UK7
and MACS3 do not have reduced CD4 dependence. Thus, Envs
with reduced CD4 dependence are more frequent in brain but
are also present in lymphoid tissues of some AIDS patients with
HAD. These results contrast with previous reports that
identified Envs with reduced CD4 dependence only in brain
(Martin-Garcia et al., 2006; Peters et al., 2004; Peters et al., in
press), a discrepancy that may be explained in part by the larger
number of functional Env clones analyzed in our study. In
addition to having reduced CD4 dependence, MACS2 and UK7
brain Envs were also more efficient at utilizing low CCR5
compared with lymphoid Envs. Moreover, a subset of both
brain and lymphoid UK1 Envs had a greatly enhanced capacity
to use low CCR5 compared to Envs from the other 3 patients.
The finding that Envs with reduced CD4 dependence are more
frequent in brain than in lymphoid tissues suggests that viral
adaptation to the CNS microenvironment selects for viruses
with an enhanced capacity to enter cells expressing low levels ofthese receptors. However, interpatient variability in the capacity
of Envs with reduced CD4 dependence to use low CCR5
suggests that complex interdependent relationships exist
between CD4 and CCR5 dependence, as has been described
for primary HIV isolates (Kozak et al., 1997; Platt et al., 1998).
Reduced CD4 dependence has been associated with
increased macrophage tropism of HIV and SIV (Bannert et
al., 2000; Gorry et al., 2002; Peters et al., 2004; Puffer et al.,
2002). Furthermore, brain Envs with reduced CD4 dependence
are macrophage-tropic (Gorry et al., 2002; Peters et al., 2004).
We found that UK1 Envs mediated higher levels of entry into
MDM than Envs from the other 3 patients, suggesting that their
greatly enhanced capacity to use low CD4 and CCR5 levels
contributed to their increased M-tropism. However, the ability
of Envs across the entire data set to mediate entry into MDM did
not show a consistent correlation with reduced dependence on
CD4 or CCR5. Rather, the capacity of Envs from both brain and
lymphoid tissues to mediate entry into macrophages correlated
with overall fusion activity at all levels of CD4 and CCR5. The
majority of productive entry into MDM results from virion
fusion at the plasma membrane. However, virion internalization
in these cells also occurs via macropinocytosis and vesicular
uptake into the endocytic pathway (Marechal et al., 1998, 2001;
Schaeffer et al., 2004). HIV entry via the endocytic pathway
usually does not lead to productive infection (Marechal et al.,
1998). Thus, virus entry via this alternative pathway is unlikely
to account for the lack of consistent correlation between MDM
entry and reduced CD4 dependence. Together, these findings
suggest that the M-tropism of Env clones from brain and
lymphoid tissue is dependent not only on the ability to use low
receptor levels, but also on additional factors that influence the
overall efficiency of fusion. Such factors may include the ability
to utilize different isoforms or modified forms of CD4 and
CCR5 expressed on MDM (Bannert et al., 2001; Farzan et al.,
1999; Lynch et al., 2006; Mummidi et al., 1998), efficiency of
binding to cell surface virion attachment factors such as
syndecans and type C lectins (Baribaud et al., 2001; Saphire
et al., 2001) and the kinetics of gp120 conformational
rearrangements and gp41 six-helix bundle formation (Platt et
al., 2005; Reeves et al., 2004).
Functional env genes from brain and lymphoid tissue of 4
patients in our study showed distinct tissue specific compart-
mentalization. However, envs from viruses isolated from brain
of MACS2, UK1 and UK7 by coculture with PBMC were
distinct from sequences amplified directly from brain tissue,
suggesting that viral selection or adaptation occurred during
coculture. This was particularly evident for env genes from the
MACS2 brain isolate (Br4, Br9 and Br13), which were more
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from brain sequences. The phenotype of the MACS2 virus
isolate Envs was also more similar to that of lymphoid Envs
from this patient, as these Envs did not exhibit reduced CD4/
CCR5 dependence. Similarly, nef genes amplified from the
MACS2 brain virus isolate were unlike nef sequences directly
amplified from brain tissue but were similar to nef sequences
from lymphoid tissue (Agopian et al., in press). The isolation of
this virus from MACS2 brain tissue could be the result of
selection in the PBMC coculture of virus present in conta-
minating blood vessels that contained blood or lymphoid env
sequences. UK1 envs were amplified from both frontal lobe and
basal ganglia regions of brain. The env genes from these brain
regions were genetically distinct, consistent with previous
reports of genetically distinct HIV sequences in different
regions of brain (Morris et al., 1999; Salemi et al., 2005;
Shapshak et al., 1999). The basal ganglia is the brain region
most severely affected by HIVencephalitis (Berger and Arendt,
2000; Berger and Nath, 1997; Brew et al., 1995). One basal
ganglia Env, BG3-13, exhibited enhanced entry into MDM, but
other Envs cloned from this region did not exhibit enhanced
macrophage tropism or increased cytopathicity compared to
those from matched frontal lobe. Thus, other mechanisms are
likely to explain the preferential susceptibility of this region to
HIV-induced neurological injury.
In our data set, proline at position 308 in the V3 region of
gp120 was associated with brain compartmentalization in 3
patients. P308 was present in 100% of brain Envs, but only
28% of lymphoid Envs from these patients. We also found a
higher frequency of P308 in brain (51%; n=135) compared
with matched non-brain (37%; n=125) Env sequences when
we analyzed data sets from several previous studies (p=0.01,
Fisher's exact test) (Donaldson et al., 1994; Gartner et al.,
1997; Korber et al., 1994; Martin-Garcia et al., 2006; Morris
et al., 1999; Peters et al., 2004; van't Wout et al., 1998; Wang
et al., 2001). Power et al. (1995) reported an association
between the amino acid residues at positions 308 and 332 with
clinical signs of AIDS dementia, but other studies have
questioned the role of a specific amino acid at position 308 in
neurotropism (Di Stefano et al., 1996). However, further
evidence implicating amino acid alterations at position 308 in
viral adaptation to the CNS was recently described in a
comparison of CSF and plasma samples (Pillai et al., in press;
Strain et al., 2005). In this study, proline at position 308 was
present in Envs from 4 patients with compartmentalized env
sequences and proline was significantly correlated with CSF
origin (31/43 in CSF and 2/48 in plasma, p<0.001, Fisher's
exact test) (Pillai et al., in press). A proline at position 308
was reported in V3 loop sequences from astrocytes but not
macrophages/microglia microdissected from brain of one
HAD patient (Thompson et al., 2004), raising the question
of whether latent HIV within astrocytes may be the source of
some sequences amplified in our study. Our data combined
with studies of matched CSF and plasma samples imply that
proline at position 308 in the V3 loop is a shared signature
sequence resulting from adaptation to the brain microenviron-
ment in some HIV-infected individuals.Position 308 lies at the tip of the V3 loop and thus may be
involved in interaction with the chemokine coreceptor. How-
ever, it is not a position used for genotyping Envs for CCR5 or
CXCR4 usage (Jensen et al., 2003; Resch et al., 2001). The
importance of this residue in modulating Env interactions with
CCR5 was highlighted by an in vitro generated escape mutant
from the CCR5 small molecule inhibitor AD101, with a
mutation of histidine to proline at position 308 conferring
resistance (Kuhmann et al., 2004; Marozsan et al., 2005; Trkola
et al., 2002). However, mutation of P308 to histidine in brain
Envs from MACS2 and UK7 did not alter sensitivity to CCR5
inhibitors. This result suggests that escape from coreceptor
inhibitors resulting from alterations in single residues in HIV
Env is context dependent.
Molecular modeling of the JRFL gp120-CD4-CD4i Ab X5
complex crystal structure (2B4C) with Swiss PDB Viewer
(http://ca.expasy.org/spdbv) suggests that introduction of a
proline at position 308 induces minor conformational changes
in V3 that result in a slightly more open conformation of the V3
tip region (R. Dunfee and D. Gabuzda, unpublished data). This
conformation may allow for increased exposure of the
coreceptor binding site or increased exposure of neutralizing
epitopes in the N-terminus of V3. Consistent with this model,
P308 in conjunction with a methionine at position 309 has been
implicated in inducing a more open conformation of HIV Env,
resulting in CD4 independence and increased elicitation of
broadly neutralizing Abs by a primary HIV Env (Quinnan et al.,
1999; Young et al., 2004; Zhang et al., 2002). Envs from
MACS2 brain and UK1 brain and spleen contain the P308/
M309 motif but did not mediate CD4-independent infection.
However, mutagenesis of P308 to histidine in a MACS2 brain
Env decreased sensitivity to neutralizing sera. A microglia-
adapted virus, Bori-15, is also more sensitive to serum
neutralization (Martin et al., 2001), suggesting that adaptation
of brain Envs to the reduced receptor levels on target cells in the
brain may result in enhanced exposure of neutralizing epitopes.
In the periphery, sensitivity to neutralization by serum
antibodies would likely be lethal to an evolving virus. However,
the CNS is an immunologically privileged site, with lower
neutralizing activity than plasma (Goudsmit et al., 1987; Pillai
et al., in press). Therefore, mutations such as P308 may persist
in the CNS even if they expose neutralization-sensitive
epitopes. Understanding the selective pressures on evolution
of the HIV envelope glycoproteins within the brain micro-
environment may facilitate not only a better understanding of
mechanisms that determine viral tropism for specific target cells
and neutralizing epitopes, but also the development of
therapeutics to target neurological injury in AIDS patients.
Materials and methods
Tissue samples
MACS2 and MACS3 were participants in the Chicago
component of the Multicenter AIDS Cohort study (MACS)
(Gorry et al., 2001, 2002). Tissue samples from patients UK1
and UK7 were obtained from the Edinburgh MRC HIV Brain
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Autopsy brain and lymphoid tissue samples were stored at
−80 °C. Clinical characteristics of patients and tissue samples
are shown in Table 1.
Cells
293T, Cf2th (a canine thymocyte cell line) (Choe et al.,
1996) and HeLa clone JC53 expressing high levels of CD4 and
CCR5 (Platt et al., 1998), provided by D. Kabat, were cultured
in Dulbecco's modified Eagle medium supplemented with 10%
(vol/vol) fetal bovine serum and 100 μg of penicillin and
streptomycin per ml. Cf2-Luc cells (Etemad-Moghadam et al.,
2000), derived from Cf2th cells, stably express the firefly
luciferase gene under the control of the HIV long terminal
repeat and were cultured in medium containing 0.7 mg/ml of
G418 (Mediatech, Herndon, VA). Cf2/CD4/R5 cells stably
expressing CD4 and CCR5 were cultured in medium containing
0.4 mg/ml of G418 and 0.15 mg/ml of hygromycin (Roche,
Indianapolis, IN). Monocyte-derived macrophages (MDM)
were purified from PBMC by plastic adherence and cultured
for 5 days in RPMI 1640 medium supplemented with 10% fetal
bovine serum, 100 μg of penicillin and streptomycin per ml and
10 ng/ml macrophage colony stimulating factor (R and D
Systems, Minneapolis, MN).
PCR amplification, HIV Env cloning and sequence analysis
Genomic DNA was extracted from tissue samples using
Puregene DNA Purification kit (Gentra Systems, Inc., Minnea-
polis, MN). HIV Gag DNA copy number per 106 cells was
determined with TaqMan Universal PCR Master Mix (Applied




length Env genes were amplified from genomic DNA and
cloned into pCR3.1 as described (Gorry et al., 2002). Env
clones were sequenced using DYEnamic ET Terminator Cycle
Sequencing kit (GE Healthcare, Piscataway, NJ) on an Applied
Biosystems 3100 Genetic Analyzer (Foster City, CA).
Western blot
Analysis of Env expression was performed as described
(Gorry et al., 2002). Briefly, 293T cells were transfected with
pCR3.1Env clones and 72 h after transfection were rinsed twice
in PBS and resuspended in lysis buffer (Gorry et al., 2002).
Equal amounts of cell lysates were run on SDS–PAGE gels and
analyzed by western blotting with rabbit anti-gp120 polyclonal
sera (provided by J. Sodroski).
Cell–cell fusion assay
Env-mediated fusion was quantitated as described pre-
viously (Gorry et al., 2002). Briefly, 293T cell cotransfected
with pCR3.1Env and pLTR-Tat were mixed with Cf2-Luc cellscotransfected with 0.05 (low), 0.5 (medium) or 5 μg (high)
amounts of pcDNA3-CD4 and pcDNA3-CCR5 resulting in low,
medium or high cell surface expression of CD4 and CCR5 as
determined by flow cytometry. Fourteen to sixteen hours later,
cells were harvested and assayed for luciferase activity
(Promega, Madison, WI).
Single round infection with pseudotyped viruses
To screen for functional Env clones, 293T cells were
cotransfected with pCR3.1Env and pNL4.3ΔenvGFP. GFP
pseudoviruses were harvested 72 h after transfection and used to
infect JC53 cells. GFP-positive cells were detected by
fluorescence microscopy 48–72 h after infection. Luciferase
pseudotyped viruses were produced by cotransfection of 293T
cells with pCR3.1Env clones and pNL4.3ΔenvLuc. Luciferase
pseudoviruses were harvested 72 h after transfection and used to
infect Cf2 cells transfected with CD4 and either CCR5, CXCR4
or CCR3. 72 h later, cells were harvested and assayed for
luciferase activity. MDM were harvested and assayed for
luciferase activity 6 days after infection with luciferase
pseudoviruses.
Virus inhibition and neutralization assays
CCR5 inhibitors AD101 (SCH 350581, provided by
Schering-Plough Research Institute, Kenilworth, NJ), TAK-
779 and 2D7 (both obtained through the AIDS Research and
Reference Reagents Program, Division of AIDS, NIAID, NIH,
Bethesda, MD) were preincubated with Cf2/CD4/R5 target cells
for 1 h prior to infection with luciferase pseudoviruses. For T20
(from Roche, obtained through the AIDS Research and
Reference Reagents Program) and human monoclonal Abs
against HIV Env, virus was incubated with for 1 h with a range
of concentrations of T20 or each MAb prior to infection of Cf2/
CD4/R5 cells. 72 h later, cells were harvested and assayed for
luciferase activity. MAb b12 (Roben et al., 1994) and 2F5
(Buchacher et al., 1994; Purtscher et al., 1994) were obtained
though the AIDS Research and Reference Reagents Program
(from D. Burton and C. Barbas, and Herman Katinger,
respectively). MAbs 17b (Thali et al., 1993) and 19e (Decker
et al., 2005) were kindly provided by J. Robinson (Tulane
University Health Sciences Center, New Orleans, LA). HIV-
positive patient sera, PS1 and PS2 (Vujcic and Quinnan, 1995),
were obtained though the AIDS Research and Reference
Reagents Program from Dr. Luba Vujcic. PS3 and PS4 were
kindly provided by J. Sodroski.
Phylogenetic analysis
Sequences were aligned using VectorNTI (Invitrogen,
Carlsbad, CA) and bootstrapped phylogenetic trees were
created by the neighbor joining method using ClustalX
(Thompson et al., 1997). Trees were visualized using Treeview
(Page, 1996). Potential N-linked glycosylation sites were pre-
dicted using N-Glycosite (http://hiv-web.lanl.gov). Sequence
signatures in brain and lymphoid sequence sets were identified
116 E.R. Thomas et al. / Virology 360 (2007) 105–119using VESPA (http://hiv-web.lanl.gov) (Korber and Myers,
1992).
Nucleotide sequence accession numbers
GeneBank accession numbers for gp160 nucleotide and
amino acid sequences are DQ976380–DQ976434. gp160
sequences from the UK1, UK7 and MACS2 brain viral isolates
have been reported previously (Dunfee et al., in press; Gorry et
al., 2002) (UK1Br15: AF491740; UK1Br30: AF491741;
UK1Br32: AF491742; MACS2Br4: AF491738; MACS2Br9:
AF491739; MACS2Br13: AF491737).
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